Thermo Fisher Scientific maintains recent strong performance in Q3 2014

Thermo Fisher Scientific has announced its financial results for the third quarter of 2014, during which it generated a revenue total of $4.17 billion (2.59 billion pounds).

This represented a year-on-year increase of 31 percent, while its adjusted earnings per share rose by 32 percent to $1.71 and its adjusted operating margin increased by 250 basis points to 21.9 percent.

During the period, the firm was able to achieved a breakthrough in ultrahigh-performance liquid chromatography with the launch of the Thermo Scientific Vanquish system, while continuing its progress with the integration of Life Technologies.

It was also able to progress its efforts to expand the market reach of its next-generation sequencing technologies with the launch of the Ion PGM Dx system and reagents for clinical use in the US and Europe.

Marc Casper, president and chief executive officer of Thermo Fisher Scientific, said: "We leveraged our solid top-line results and our culture of operational discipline to achieve excellent performance on the bottom line."

Last month, the firm also announced a new alliance with pharmaceutical giants GlaxoSmithKline and Pfizer to develop oncology companion diagnostics using next-generation sequencing.